Phenomenal 👏
PVC localization has been one of the harder things to learn and teach as a cardiology fellow interested in EP.
So I built learnpvcs.com to help connect the 12-lead ECG with 3D cardiac anatomy.
You can explore different PVC origins, rotate and look inside the heart, and work through practice cases.
It's an early educational prototype, and I'd love feedback from fellows, electrophysiologists, and educators.
Which PVC origin do you find hardest to localize?
#CardioTwitter #EPeeps #MedEd @OpenAI @WvuCvFellows @wvudeptofmed
A good answer could be: “well, my name is…, did med school at….where I absolutely loved doing….I particularly enjoy (name a hobby, great if it ties into the location of the program)”
Really ought to tell this beforehand so candidates that don’t intend on signaling don’t even apply and save some 💵 🤦♂️
Was asked about LORs by some applicants. This still holds true! #Match2027
Got asked by some applicants about Letters of recommendations. LORs can often break or make your ERAS application. Follow these tips to maximize your LORs. 🧵 #Medtwitter #Match2024
Moiz Ehtesham, MD retweeted
This is an amazing capture of ventricular fibrillation on echo
Rare glimpse of echocardiogram just at the onset of VF, no organized heart activity and....
#cardiotwitter #MedTwitter
Things I learned today - if ever concerned for CTEPH, always check for APLA antibodies! #boards
A very good thinking!
Mayo Clinic Echo Lab now recommends measuring a single highest velocity of aortic valve and LVOT to determine AV gradient and AVA. Hope this will become a part of future VHD guideline @ottoecho
Replying to @JaeKOh2 @alsidawimd
I’ve been thinking a lot about this. To me using highest gradient makes more sense as AF by itself brings down the cardiac output, in low flow we give dobutamine to increase flow and gradient. Here long R-R cycle could serve as such
Moiz Ehtesham, MD retweeted
When conventional approaches are limited, there are always options.
A completely leadless CRT-D strategy ⚡️
Micra AV + Aurora EV-ICD + WiSE-CRT
@EBRSystemsInc @MDT_Cardiac @TulaneTriad @TulaneMedicine @SheaQarqish @nmarrouche
Moiz Ehtesham, MD retweeted
A huge congratulations to our graduating LUMC cardiology fellows! 🎉 We’re so proud of all you’ve accomplished and can’t wait to see what’s next. Wishing you continued success and happiness in the years ahead! 🫀#loyolacardiology
Moiz Ehtesham, MD retweeted
If you are South Asian, please sign up for @ourhealthstudy
Let’s start understanding heart disease in our community now!
Get your families to sign up too. Super simple! And for those of our attending #ASPC2026 you can participate on the spot! @ASPCardio
❤️ Did you know? People of South Asian ancestry have TWICE the risk of heart disease and diabetes compared to other groups.
The @ourhealthstudy Research Study is working to change that — using genetics to understand why, and to find better solutions.
📋 Participating is simple:
1️⃣ Consent online
2️⃣ Complete health surveys
3️⃣ Donate a saliva sample (mailed to you!)
Your data is kept secure and confidential. Join the study and help shape the future of South Asian heart health. 🧬
👉 Learn more & sign up: ourhealthstudy.org
📧 Questions? [email protected]
#OurHealth #SouthAsian #HeartHealth #HealthEquity #ResearchStudy #Genetics #MassGeneralBrigham
Moiz Ehtesham, MD retweeted
One of our rising LUMC cardiology chiefs, @PunitAroraMD, presented a case on the management of a fractured coronary guidewire during PCI at SCAI in 🇨🇦 this past week, strong work! @DSutherlandMD #ElizabethBruno
Moiz Ehtesham, MD retweeted
📢LBCT ASCEND CSP #HRS2026 (+ Simultaneous pub @hrs_journal) @rdschaller @Drdevignair @pvijayaraman1 @HRSonline #SciComms
*⃣Another step toward true physiologic ICD therapy:
👉 A purpose-built, stylet-driven CSP ICD lead by Abbott for LBBAP
➡️Prospective, global IDE trial (n=205)
• Implant success: 98.5%
• LBBAP achieved: 99% (86% true/likely LBB capture)
• Primary effectiveness: 94.6% (exceeded 80% goal)
• Stable thresholds + sensing at 3 months
➡️Defibrillation performance (critical for ICD adoption):
• 100% DFT success
• 92.5% terminated with single 20J shock
👉 No compromise in shock efficacy despite septal lead position
➡️Safety signal:
• 97.5% complication-free at 3 months
• Events included:
– 2 lead dislodgements
– 1 septal perforation (LV entry, required lead removal)
– 1 helix mechanical failure
– 1 drop in R-wave amplitude
➡️Clinical Implication:
✴️This is the first dedicated, stylet-driven bipolar ICD lead engineered for CSP, specifically modified for septal/LBBA implantation
✴️Potential to enable physiologic ICD or LOT-CRT
⚠️ Caveats:
• Single-arm (no RV lead comparator)
• Short follow-up (3 months)
• Operator-dependent CSP success
• Unknown long-term durability, extractability, and TR impact
heartrhythmjournal.com/artic…































